MedPage TodayCytokinetics, Inc. (CYTK): Cytokinetics: Presentation At Heart Failure Society …Seeking AlphaCytokinetics (CYTK) and Amgen (AMGN) first presented data from the ATOMIC HF trial at the European Society of Cardiology Congress (ESC) on Septe…
University of Michigan Cardiovascular study shows DASH diet improves heart … – Newswise (press release)
|
University of Michigan Cardiovascular study shows DASH diet improves heart …
Newswise (press release) Diet can dramatically lower hypertension and improve heart function in patients with a common type of heart failure, according to research presented at today’s Heart Failure Society of America meeting in Orlando, Fla. After 21 days of following a low … |
Full-dose beta-blockers still show heart failure benefit – Family Practice News Digital Network
|
Full-dose beta-blockers still show heart failure benefit
Family Practice News Digital Network AMSTERDAM – Patients with heart failure appeared to continue to benefit from full-dose beta-blocker therapy against a background of optimal, contemporary treatment, based on an analysis of data collected from an 1,800-patient trial of cardiac … |
Some childhood cancer survivors may face subsequent renal problems – Science Codex
Some childhood cancer survivors may face subsequent renal problemsScience CodexThe researchers found that compared with CCS who did not receive kidney-damaging treatments, those who were treated with ifosfamide or cisplatin and those who underwent neph…
Inflammatory marker may highlight aggressive RCC treatment need – medwireNews
|
Inflammatory marker may highlight aggressive RCC treatment need
medwireNews Molecular-targeted agents were approved in Japan in 2008, so 51.2% of the patients received such treatments following cytoreductive nephrectomy, whereas the others were given immunotherapy. Receipt of targeted agents doubled patients’ chances for … |
Dose-Dense Regimen Does Not Improve R-CHOP for DLBCL – Clinical Oncology News
Clinical Oncology NewsDose-Dense Regimen Does Not Improve R-CHOP for DLBCLClinical Oncology NewsThe addition of rituximab (Rituxan, Genentech) to the regimen (i.e., R-CHOP) was found to improve cure rates by 10% to 15%. Researchers from the United King…
Death of the Brain Is Not the Death of the Human Being – Medscape
Medscape |
Death of the Brain Is Not the Death of the Human Being
Medscape As long as we continue to insist that patients must be dead before we take their organs for transplant (the “dead donor rule”), determining whether they are dead (or not) is of the utmost importance. But it is also quite difficult. The longer a medical … |
Living better with heart failure by changing what you eat – University of Michigan Health System News (press release)
University of Michigan Health System News (press release) |
Living better with heart failure by changing what you eat
University of Michigan Health System News (press release) ANN ARBOR, Mich. – Diet can dramatically lower hypertension and improve heart function in patients with a common type of heart failure, according to research presented at today’s Heart Failure Society of America meeting in Orlando, Fla. After 21 days … |
Wait list mortality higher for female heart transplant candidates – Healio
|
Wait list mortality higher for female heart transplant candidates
Healio In the past decade, the proportion of women on the wait list for heart transplantation has increased by 4.2%, Morris said. – by Erik Swain. For more information: Morris AA. Abstract #207. Presented at: the Annual Scientific Meeting of the Heart Failure … |
Biomarker IDs Fibrotic Heart Failure – MedPage Today
Biomarker IDs Fibrotic Heart FailureMedPage TodayLevels of Gal-3 were significantly more elevated in patients with cardiac amyloidosis compared to those with left ventricular (LV) hypertrophy (P<0.050) and those with systolic heart failure (P<0.0…